In summary, ICT appears to function through a dual regulatory strategy: “suppressing malignancy” by downregulating pro-oncogenic genes (CA9, UCK2, and FABP5), and “reinforcing physiological function” by upregulating the potential tumor suppressor CYP2C9. This evidence concerns the gene UCK2 and neoplasm.